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Abstract 
Diffuse gliomas are represented in the 2007 WHO classification as astrocytomas, oligoastrocytomas 
and oligodendrogliomas of grades II and III and glioblastomas WHO grade IV. Molecular data on these 
tumors have a major impact on prognosis and therapy of the patients. Consequently the inclusion of 
molecular parameters in the WHO definition of brain tumors is being planned and has been forwarded 
as the “ISN-Haarlem” consensus. We here analyze markers of special interest including ATRX, IDH 
and 1p/19q co-deletion in a series of 405 adult patients. Among the WHO 2007-classified tumors were 
152 astrocytomas, 61 oligodendrogliomas, 63 oligoastrocytomas and 129 glioblastomas. Following the 
concepts of the “ISN-Haarlem” we re-diagnosed the series to obtain “integrated” diagnoses with 155 
tumors being astrocytomas, 100 oligodendrogliomas and 150 glioblastomas. In a subset of 100 diffuse 
gliomas from the NOA-04 trial with long term follow up data available, the “integrated” diagnosis had a 
significantly greater prognostic power for overall and progression free survival compared to WHO 
2007. Based on the “integrated” diagnoses, loss of ATRX expression was close to being mutually 
exclusive to 1p/19q co-deletion, with only 2 of 167 ATRX-negative tumors exhibiting 1p/19q co-
deletion. All but 4 of 141 patients with loss of ATRX expression and diffuse glioma carried either IDH1 
or IDH2 mutations. Interestingly, the majority of glioblastoma patients with loss of ATRX expression 
but no IDH mutations exhibited an H3F3A mutation. Further, all patients with 1p/19 co-deletion carried 
a mutation in IDH1 or IDH2. We present an algorithm based on stepwise analysis with initial 
immunohistochemistry for ATRX and IDH1R132H followed by 1p/19q analysis followed by IDH 
sequencing which reduces the number of molecular analyses and which has a far better association 
with patient outcome than WHO 2007. 
 
Introduction 
 
Brain tumor classification of diffuse astrocytic and oligodendroglial tumors 
The classical way of diagnosing diffuse astrocytoma and oligodendroglial tumors adheres to the World 
Health Organization (WHO) 2007 guidelines [29]. Along these lines, the calling of oligoastrocytoma 
poses great problems best seen in the extensive interobserver variance regarding use of this 
diagnosis [13,14,37]. Ever since the association of 1p/19q loss with more favorable prognosis was 
proposed [9], a dramatic increase of the diagnosis “oligoastrocytoma” has been observed and 
deserves critical questioning [7]. On the other hand, clinical studies have repeatedly demonstrated the 
1p/19q status of oligodendroglial tumors to be of more prognostic or predictive value than the 
differentiation between oligodendroglioma and oligoastrocytoma [8,45,50]. Further, a recent study 
demonstrated that the majority of IDH mutated oligoastrocytoma can be resolved as either 
astrocytoma or oligodendroglioma by histological methods [40]. A novel approach for more stringently 
diagnosing diffuse astrocytoma and oligodendroglial tumors has been outlined in the recently 
published “ISN-Haarlem” Guidelines. 
 
“ISN-Haarlem” Guidelines 
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In order to discuss the inclusion of molecular data into the next World Health Organization (WHO) 
classification of central nervous system tumors, a meeting under sponsorship of the International 
Society of Neuropathology (ISN) has been held in Haarlem, the Netherlands [30]. Central to the 
consensus “ISN-Haarlem” guidelines is the proposal to define diagnostic entities as narrowly as 
possible and to include, where applicable, molecular data to come up with an “integrated diagnosis”. 
This could lead, for example, to a classification separating astrocytoma and oligodendroglioma into 
groups based on IDH1/IDH2 mutation and 1p/19q status, leaving aside a probably small group of 
tumors tentatively called “diffuse glioma, not otherwise specified”. 
 
IDH1 and IDH2 and G-CIMP 
IDH1 mutations were first reported in an exome sequencing study on glioblastoma, predominantly in 
so called secondary glioblastoma with a history of a lower grade precursor tumor [36]. A high 
incidence of IDH1 mutations was subsequently established for diffuse astrocytoma, oligoastrocytoma 
and oligodendroglioma [2,6,19,48,55]. IDH2 mutations are much less frequent but occur in the same 
set of brain tumors [17,55]. The relevance of IDH1 mutations as a favorable prognostic marker has 
been demonstrated in several studies [16,41,49,50]. Since IDH1 mutations of the R132H type 
constitute more than 90% of all IDH1 and IDH2 mutations in glioma [17], the development of a 
mutation specific antibody greatly advanced the determination of IDH1-status in neuropathological 
diagnosis [12]. Due to the extraordinarily high lineage specificity of IDH1 and IDH2 mutations for 
diffuse astrocytoma, oligoastrocytoma and oligodendroglioma, IDH1 immunohistochemistry (IHC) is 
widely applied and has developed into a backbone for differential diagnosis of glioma [10,11]. 
The glioma-CpG island methylator phenotype (G-CIMP) was initially identified in glioblastomas, 
stratifying into a G-CIMP positive cluster with better outcomes and a G-CIMP negative cluster with 
worse prognosis [34]. All tumors with IDH mutations exhibited a G-CIMP positive phenotype which is 
due to IDH mutation-induced production of 2-hydroxyglutarate and its subsequent effects on DNA 
methylation [54]. Thus, a G-CIMP positive phenotype in glioblastoma is highly suggestive for presence 
of an IDH1 or IDH2 mutation. 
 
1p/19q codeletion 
The detection of frequent losses of chromosomal arm 19q in oligodendroglioma [47] was followed by 
the detection of 1p losses in these same tumors [4], and the recognition that these alterations 
frequently co-occur [3,27,39]. The presence of 1p and 19q deletions was later identified as a decisive 
predictor for overall survival and response to chemotherapy [9,43]. However, subsequent studies 
demonstrated that partial losses of 1p were associated with much poorer survival than loss of the 
entire arm [20]. Thus, it is now believed, that the combined and entire loss of the chromosomal arms 
1p and 19q (1p/19q loss) is the parameter associated with favorable prognosis. The basis of combined 
1p/19q loss is believed to be an unbalanced t(1;19) translocation event [15,21]. 
 
ATRX 
Somatic mutations in the alpha thalassemia / mental retardation syndrome X-linked (ATRX) gene were 
first detected in pancreatic neuroendocrine tumors (PanNET) [23], followed by pediatric glioblastomas 
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[42]. Mutation analysis of ATRX in series of adult gliomas revealed a high incidence of this alteration in 
diffuse astrocytomas opposed by a lower incidence in oligodendrogliomas, oligoastrocytomas and 
glioblastomas [22,24,25]. ATRX status in combination with 1p/19q and IDH1/IDH2 statuses has been 
used to generate a molecular diagnostic algorithm which turned out to be superior to classical 
neuropathological techniques in building patient groups with different times to treatment failure [51]. 
Commonly, ATRX mutation results in a truncated protein and in abrogated protein expression [18,28]. 
These findings suggest a considerable potential for ATRX IHC in distinguishing between diffuse 
astrocytic and oligodendroglial tumors. 
 
Aim of the study 
Several studies have identified ATRX IHC as promising tools for classifying brain tumors. However, 
their conclusions lack the desirable precision for diagnostic use due to heterogeneity of the tumor 
series examined with problems including underdiagnosed glioblastomas, the wide variation in 
diagnosing oligoastrocytomas and the shortcoming of precisely differentiating between partial and 
complete losses on chromosomal arms 1p and 19q. The current series examines ATRX expression on 
tumors stringently analyzed for molecular alterations and classified according to the Haarlem 
consensus concepts of the International Society of Neuropathology for nervous system tumor 
classification [30]. The study has two primary aims: first to establish a technical standard for ATRX 
IHC and second to establish an algorithm for using ATRX, IDH1-R132H IHC, 1p/19 analyses and IDH 
sequencing in the diagnosis of diffuse gliomas. 
 
 
Material and Methods 
 
Tissue selection 
Tumor tissues were obtained from the archives of the Departments of Neuropathology at the 
University Medical Centers of Heidelberg and Tuebingen and the Neurological Institute/Edinger 
Institute Frankfurt/Main (Germany). Research use of tissues and anonymization of data were in 
accordance with local ethical approvals. The series contains tumor tissues from 405 patients. All 
tumors were initially classified and graded according to the current WHO 2007 guidelines [29]. The 
series consisted of 152 astrocytomas, 61 oligodendrogliomas, 63 oligoastrocytomas and 129 
glioblastomas including 93 ordinary glioblastomas, 12 glioblastomas with oligodendroglial component, 
7 secondary glioblastomas 3 giant cell glioblastomas and 14 gliosarcomas. Inclusion criteria were the 
availability of tissue blocks and availability of an Illumina Infinium HumanMethylation450 BeadChip 
(450k)-based copy number profile. 100 cases from the NOA-04 trial were included [50]. Since only 
anaplastic gliomas were included in NOA-04, there is an over representation of anaplastic gliomas 
(WHO grade III) in comparison to the WHO grade II counterparts. All tumors were reevaluated in 
knowledge of the 1p/19q, 7p/10q and IDH status. This reevaluation was based on the Haarlem 
consensus concepts of the International Society of Neuropathology for nervous system tumor 
classification [30]. Final and initial diagnoses are provided in supplementary table 1. 
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Determination of 1p/19q codeletion, 7p gain, 10q loss, EGFR amplification, MGMT promoter 
methylation and G-CIMP phenotype by 450k array analysis 
The Illumina Infinium HumanMethylation450 BeadChip (450k) array was used to obtain the DNA 
methylation status of 482,421 CpG sites (Illumina, San Diego, USA) according to the manufacturer’s 
instructions at the Genomics and Proteomics Core Facility of the DKFZ. The array data was used to 
calculate a low-resolution copy number profile as previously described [44]. The probability of MGMT 
promoter methylation from 450k array data was estimated as previously described [1]. 334 cases were 
scored as methylated or unmethylated, in 71 cases the methylation status was unsure. Further, the 
data were analyzed as previously described to allot the tumors to either a G-CIMP or a non-G-CIMP 
cluster [53].  
 
IDH1/IDH2, H3F3A and TERT promoter mutation analyses 
Primer design for sequencing was based on accession numbers NM_005896 for IDH1, NM_002168 
for IDH2, NM_002107.4 for H3F3A (http://www.ncbi.nlm.nih.gov). Primers for H3F3A: forward 5’-
CATGGCTCGTACAAAGCAGA-3’; reverse 5’-CAAGAGAGACTTTGTCCCATTTTT-3’. PCR and 
sequencing was performed as previously described [17]. A 163 bp fragment of the TERT promoter 
region spanning the hotspot mutations at positions 1,295,228 and 1,295,250 on chromosome 5 was 
amplified by using GoTaq G2 Hot Start Polymerase (Promega, Madison, USA) and the primers 
hTERT-short-for 5´-CAGCGCTGCCTGAAACTC-3´ and hTERT-short-rev, 5’-
GTCCTGCCCCTTCACCTT-3’ as previously described [26]. Sequences were determined using a 
semi-automated sequencer (ABI 3100 Genetic Analyzer, Applied Biosystems, Foster City) and 
Sequence Pilot version 3.1 (JSI-Medisys, Kippenheim, Germany) software. 
 
Immunohistochemistry  
Immunohistochemistry was conducted on 4 µm thick formalin-fixed, paraffin-embedded (FFPE) tissue 
sections mounted on StarFrost Advanced Adhesive slides (Engelbrecht, Kassel, Germany) followed by 
drying at 80°C for 15 min. Immunohistochemistry was performed on a BenchMark Ultra immunostainer 
(Ventana Medical Systems, Tucson, AZ, USA). Sections were stained with anti-IDH1-R132H antibody 
H09 (Dianova, Hamburg, Germany) as previously described [11]. 
For ATRX immunohistochemistry we tested several commercially available antibodies. In our hands 
the antibody with best specificity for diagnostics is HPA001906 (Sigma-Aldrich, St. Louis, MO; USA). 
In brief, after deparaffinization, slides were pretreated at 95°C in Cell Conditioning 1 buffer (Ventana) 
for 90 minutes. The sections were incubated with primary antibody (diluted 1:200) for 2 hours. 
Standard Ventana signal amplification was used. The protocol is provided in supplementary file 2. To 
test for specificity we used tumors with ATRX mutations confirmed by DNA sequencing. Loss of 
nuclear ATRX expression was scored as specific if tumor cell nuclei were unstained while nuclei of 
non-neoplastic cells such as endothelia, microglia, lymphocytes and reactive astrocytes were strongly 
positive. Of note, moderate staining of tumor cell cytoplasm may occur which most likely is unspecific. 
However, cytoplasmic staining does not hamper the interpretation of nuclear staining. Parameters to 
augment staining intensity are increase of antibody concentration, prolongation of pretreatment and of 
first antibody incubation times. Occasionally, ATRX staining is limited to circumscribed regions of the 
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tissue, most likely due to artificial tissue damage. Evaluation of these partially stained cases seems to 
be still meaningful because heterogeneous ATRX staining is virtually never observed. In the present 
study only a single case of gliosarcoma showed a focal loss of ATRX positivity. 
Reagents and staining protocols for IDH1-R132H and ATRX are listed in supplementary file 1. 
 
Statistics 
Kaplan-Meier estimator and Cox proportional hazards regression were performed to assess survival 
data. To compare the performance of Cox regression models, integrated Brier scores displayed as 
prediction error curves over time were generated using the R package pec [33] (using the 
“Boot632plus” split method with 1000 iterations). Briefly, the Brier score represents a weighted 
(roughly based on the probability of being censored) average of the squared error between estimated 
survival probability at each time point and observed survival status. All analyses were carried out using 
R version 3.11 [38]. Fisher's exact test was used to explore associations between ATRX status and 
tumor entities or molecular markers. 
 
 
Results and Discussion 
Several studies have pointed towards the role of ATRX analysis for the diagnosis of diffuse glioma. 
Especially ATRX immunohistochemistry has shown promising results [51].  In order to test the impact 
on routine diagnostic neuropathology we here analyzed a series of 154 astrocytomas, 100 
oligodendrogliomas and 150 glioblastomas by immunohistochemistry for ATRX expression. 
Immunohistochemical results were compared with the hallmark markers IDH1/IDH2, 1p/19q 
codeletion, 7p gain, 10q loss, TERT promoter, EGFR amplification and H3F3A status. 
 
Detection of combined 1p/19q loss and detection of IDH mutations 
Detection and scoring of combined 1p/19q losses relies on different methods. FISH is probably the 
most frequently used because this method needs the fewest adaptations to what is available in routine 
diagnostic laboratories. However, FISH has a major conceptual weakness because reliable 
information on the integrity of the analyzed chromosome is only obtained on the region the FISH probe 
is hybridizing to. Thus it cannot be used to clearly distinguish between partial and complete losses of a 
chromosomal arm. Classical microsatellite analysis with several probes spanning the targeted 
chromosome may mostly circumvent this shortcoming; however this is a tedious approach requiring 
time, labor and DNA for several rounds of PCR [31]. Multiplex ligation-dependent probe amplification 
(MLPA) reduces needs for time and material but frequently yields ambiguous results in our hands. The 
most comprehensive approach allowing data collection on a large set of chromosomal regions is array 
technology with multiple companies offering solutions. We have adopted an algorithm allowing the 
generation of a copy number profile (CNP) from hybridizing bisulfite converted DNA to 450K Illumina 
chips. These CNP provide information on 473 regions on chromosomal arm 1p and 166 regions on 
chromosomal arm 19q, allowing us to distinguish normal copy number and partial or complete 
underrepresentation of chromosomal arms with high confidence. Comparison of MLPA and 450k-
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CNP-based 1p/19q analysis indicated that the latter method more accurately assessed 1p/19q status 
[52]. Comparable CNP can also be calculated from exome or genome sequencing data sets, but these 
are more costly and require greater analytical expertise, and are also not so readily applicable to 
FFPE DNA. Of importance for 1p/19q evaluation is the extent of the deletions on 1p and 19q: There is 
now general agreement that these losses need to encompass the entire arms, as partial losses have 
been observed frequently in other gliomas. For example, partial losses of 1p are frequent in 
glioblastoma and partial losses of 19q are frequently seen in anaplastic astrocytomas WHO grade III 
[46]. Further, partial losses on 1p have been shown to be associated with poorer survival, in  contrast 
to the favorable prognostic association of entire loss of 1p in oligodendroglioma [20]. Only tumors with 
loss of both, the entire arms of chromosome 1p and 19q were scored as co-deleted for 1p/19q (1p/19q 
codel) in this study. All other tumors exhibiting balanced profiles, loss of only either 1p or 19q, partial 
losses of either 1p or 19q, or any combination of these were scored as non-co-deleted for 1p/19q 
(1p/19q noncd). Typical examples for CNP exhibiting 1p/19q codel (tumor 1180) or partial losses on 
1p and 19q (tumor 1024) are given in figure 1. 
We have generated CNP profiles based on 450k array analysis for all 405 cases included in this study. 
Combined 1p/19q loss was detected in 100 cases (supplementary table 1). All 405 cases were 
subjected to IHC using antibody H09 directed at IDH1-R132H protein. Binding of H09 was taken as 
proof for an IDH1-R132H mutation. 205/405 tumors carried an IDH1-R132H mutation. All 
astrocytomas and oligodendrogliomas not binding H09 were subjected to sequencing of exon 4 of 
both, IDH1 and IDH2. The 16 glioblastomas with a G-CIMP positive phenotype were also subjected to 
IDH1 and IDH2 sequencing. Altogether, we detected 35 rare IDH1 and 13 IDH2 mutations. 15/16 GBM 
with G-CIMP tested positive for an IDH mutation (supplementary table 1). 
 
Establishing the “integrated” diagnosis 
All tumors were evaluated by two neuropathologists (DR, AvD) and initially classified according to the 
current WHO guidelines [29]. We then deviated from the current WHO by not accepting the diagnosis 
of oligoastrocytoma but reclassifying these tumors either as astrocytomas or oligodendrogliomas. We 
have previously shown that the vast majority of so-called oligoastrocytoma can be separated into 
astrocytoma and oligodendroglioma based on IDH1-R132H, ATRX immunohistochemistry and 
analysis of 1p/19q status [40]. Our reevaluation was carried out in the knowledge of 1p/19q, 7p/10q 
and IDH1/IDH2 status.  
Cases with 1p/19q codel were defined as oligodendroglioma and 1p/19q noncd gliomas were 
diagnosed as astrocytoma or glioblastoma depending on the presence of necrosis. Our approach 
eliminated oligoastrocytomas and glioblastomas with oligodendroglial component (GBMo) from our 
initially WHO 2007 diagnosed series. Anaplastic astrocytomas without IDH mutation and with 7p gain 
and 10q loss were defined as glioblastomas. These two lesions have been recognized for a long time 
as characteristic alterations in GBM [5] and have recently been proposed as the first molecular events 
in non-IDH-mutated GBM [35]. 
Our concept adheres to the ideas of the Haarlem consensus guidelines of the International Society of 
Neuropathology for nervous system tumor classification which will be the basis for discussion on the 
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forthcoming update of the WHO Classification [30]. This revision aims at building up more clearly 
defined tumor entities and at the inclusion of molecular data where applicable.  
Thus after reevaluation our series contained 42 diffuse astrocytomas WHO grade II, 113 anaplastic 
astrocytomas WHO grade III, 28 oligodendrogliomas WHO grade II, 72 anaplastic oligodendrogliomas 
WHO grade III, 150 glioblastomas WHO grade IV including 14 of each of gliosarcoma and 
glioblastoma with IDH mutation and 3 giant cell glioblastomas WHO grade IV (table 1). The initial and 
the integrated diagnoses for individual patients are provided in supplementary table 1. A diagram 
demonstrating the diagnostic shift is given in figure 2. 
 
ATRX expression 
We tested several antibodies and staining conditions. In our hands, best results were obtained with 
"HPA001906" and processing on a Ventana Benchmark. For the evaluation of ATRX 
immunohistochemistry, only nuclear staining was assessed. Loss of ATRX in tumor cells presents with 
a typical pattern – all tumor cell nuclei are completely unstained while nuclear positivity is seen in 
vessels, microglia, reactive astrocytes and entrapped neurons. ATRX immunohistochemistry is 
significantly affected by the quality of material - tumor portions not sufficiently fixed or thermally altered 
do not provide satisfactory results. In our experience, however, most tissue blocks contain areas with 
tumor tissue of sufficient quality for evaluation. In regard to tumor cell content in a sample for ATRX 
evaluation: We did not systematically assess ATRX loss in the infiltration zone of astrocytoma, 
however, we advise to perform such analysis preferably in solid tumor tissue. We consider this method 
not suitable for the analysis of single cells. We detected only one single case with focal ATRX loss that 
could not be attributed to suboptimal quality of the material. Thus, we assume focal loss of ATRX 
expression to be diagnostic if internal controls in these regions such as endothelia or microglia 
demonstrate nuclear staining. In our series, 38/42 (90%) of WHO II and 101/113 (89%) of WHO III 
astrocytomas presented with loss of ATRX expression. In contrast, 0/28 (0%) oligodendrogliomas and 
2/72 (3%) anaplastic oligodendrogliomas showed loss of ATRX. This difference is significant (p = 
1.70x10-50; Fisher's exact test). Further, 25/136 (18%) of glioblastomas and 1/14 (7%) gliosarcomas 
displayed loss of ATRX. Loss of ATRX and mutation of the TERT promoter were almost mutually 
exclusive in this series (p = 9.88x10-47; Fisher’s exact test). Typical examples for ATRX staining are 
given in figure 3. 
 
ATRX association with tumor entity depends on diagnostic approach 
Diffuse astrocytoma grade II (AII) diagnosed by WHO 2007 exhibited nuclear ATRX loss in 34/47 
(72%) and anaplastic astrocytoma (AIII) in 72/105 (69%) of the cases. Applying the “integrated” 
approach, 36/37 (97%) AII-IDHmut and 100/103 (97%) AIII-IDHmut exhibited nuclear ATRX loss. In 
contrast only 2/5 of the rare AII-IDHwt and 4/10 (40%) AIII-IDHwt exhibited nuclear ATRX loss. 
Oligodendroglioma grade II (OII) diagnosed by WHO 2007 exhibited nuclear ATRX loss in 3/25 (12%) 
and anaplastic oligodendroglioma (OIII) in 5/36 (14%) of the cases. Applying the “integrated” 
approach, 0/28 OII and 2/72 (3%) OIII exhibited nuclear ATRX loss. OAII diagnosed by WHO 2007 
exhibited nuclear ATRX loss in 5/9 and OAIII in 20/54 (37%) of the cases. Our “integrated” approach 
does not recognize the diagnosis of oligoastrocytoma anymore. This distribution clearly shows the 
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potential of ATRX status to differentiate astrocytoma from oligodendroglioma in IDH-mutated tumors 
and demonstrates the mixed composition of the WHO 2007 oligoastrocytoma groups. Independently of 
the diagnostic approach, the differences in ATRX association with a tumor entity were remarkably 
stable across tumor grades. This in fact, holds true also for 1p/19qcodel and IDH mutations. 
 
Association of ATRX expression with 1p/19q and IDH status 
Inclusion of an additional molecular basis for the generation of an integrated diagnosis in our set of 
405 tumors resulted in 6 groups. Within these groups there is strikingly little overlap of the genetic 
lesions. AII and AIII typically carry IDH mutations and exhibit loss of nuclear ATRX expression. OII and 
OIII carry 1p/19q codel and IDH mutations and only two of these tumors exhibited loss of nuclear 
ATRX expression. Interestingly, both of these cases had a wild type TERT promoter and this is typical 
for astrocytoma whereas the vast majority of oligodendrogliomas carry a TERT promoter mutation 
[25,26]. GBM and GS typically exhibit the combination of 7p gain and 10q loss accompanied by 
absence of IDH mutations and maintenance of nuclear ATRX expression. A set of 23 GBM 
demonstrated nuclear ATRX loss and among these 11 carried an IDH mutation. Interestingly, H3F3A 
mutations (4 cases with K27M and 4 cases with G34R) in glioblastoma were only seen in combination 
with nuclear ATRX loss and without IDH mutation - providing evidence for a GBM subset in adult 
patients with molecular similarities to pediatric GBM [44]. In each of the groups, a few cases did not 
match the expected pattern: One AII and 6 AIII with IDH mutation did not exhibit ATRX loss. These 
observations may be explained by hypothesizing that these tumors may carry an ATRX mutation not 
resulting in the abrogation of protein expression (e.g. a damaging missense mutation). Nine 
astrocytomas had neither IDH mutation nor ATRX loss. We assume these tumors not to represent a 
distinct biological entity but to be a mixture of rarer variants of astrocytic tumors lacking some or all 
known hallmark alterations. Many of these IDH-wt astrocytomas are likely to be variants or early 
manifestations of glioblastoma which finds support in one exhibiting 7p gain and 10q loss and one a 
H3F3A mutation. In six astrocytomas with ATRX loss, no IDH mutation could be identified, however, 
one of these had an H3F3A mutation. A group of 30 GBM did not exhibit any of the mutations tested 
for in the present study. An overview of these groups and the molecular alterations is given in figure 4. 
 
Significant differences in “overall survival” in NOA-04 patients depending on diagnostic 
approach 
Comparison of survival plots from 100 NOA-04 study patients demonstrates a significant difference 
between the WHO 2007 and the “integrated” diagnostic approaches. In regard to both overall survival 
and time to treatment failure, the “integrated” approach separates groups more stringently. In light of 
the intermediate position of oligoastrocytoma in the WHO 2007 classification it is of interest that this 
increase of stringency is achieved although oligoastrocytoma are not diagnosed anymore using the 
“integrated” diagnosis. The shift in diagnosis in WHO2007 compared to the “integrated” approach is 
demonstrated in figure 5. With classification aiming at prediction of outcome the “integrated” approach 
proves much more successful in this series (Table 2 and figure 6). To compare the performance of 
Cox regression models based on either the WHO 2007 classification or the “integrated” diagnosis, we 
calculated the integrated Brier score over time for both models and endpoints (time to treatment failure 
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and overall survival) as well as the R² for all models (supplementary table 2), which showed a 
markedly improved prediction accuracy (based on the bootstrapped Brier scores) and model fit (R²) for 
the “integrated” diagnosis.  
 
The combination of ATRX loss and IDH mutation defines the most frequent type of diffuse 
astrocytoma and progressions thereof 
The single finding of most diagnostic potential is the mutual exclusivity of 1p/19q loss and loss of 
ATRX expression, with the latter found overwhelmingly in IDH mutated astrocytomas and IDH mutated 
glioblastomas. This makes the combination of IDH mutation and ATRX loss the typical molecular 
fingerprint of diffuse astrocytoma including its manifestation having progressed towards glioblastoma. 
Likewise, the combination of IDH mutation and ATRX loss virtually excludes the presence of complete 
1p/19q loss and thus the diagnosis of oligodendroglioma in its narrower ISN-Haarlem boundaries. The 
combination of IDH mutation and ATRX loss is therefore expected to reduce the need for 1p/19q 
analysis by a significant fraction of tumors. 
 
Oligoastrocytoma 
Oligoastrocytoma is a well-established diagnosis in WHO 2007. Diagnosing tumors on the basis of 
IDH, ATRX and 1p/19q analysis according to the present suggestion groups these tumors either to 
astrocytoma or oligodendroglioma. The demonstration of 1p/19q status being of much more relevance 
to prognosis and treatment response than the morphological differentiation between astrocytoma, 
oligoastrocytoma and oligodendroglioma clearly warrants such an approach. Further, we recently 
demonstrated on a series of IDH1-R132H mutated oligoastrocytomas diagnosed at different 
institutions that these cases could be reliably allotted either to astrocytoma or oligodendroglioma 
based on molecular data [40], and an epigenome-wide analysis of a large cohort of anaplastic glioma 
further substantiated that there is no biological basis for the diagnosis of an oligoastrocytoma [53]. 
 
Glioblastoma with oligodendroglial differentiation 
Four of 12 tumors with initial diagnosis of GBMo exhibited 1p/19q codel, and were therefore classified 
as anaplastic oligodendroglioma. The remaining 8 tumors were reclassified as GBM, one of which 
carried an IDH mutation. Separation of these tumors is further supported by the observation that 
GBMo appears to have a more favorable prognosis, that gliomas with 1p/19q codel nearly inevitably 
carry an IDH mutation and that IDH mutations are the single most prognostic marker in GBM [49]. Our 
approach aims at classification, however it does not solve grading problems. Interestingly, the 
presence of necrosis appears to be no predictor for poorer overall survival in anaplastic 
oligodendroglioma [32]. Whether the GBMo reclassified as anaplastic oligodendroglioma should be 
allotted a WHO grade higher than III needs to be addressed in further studies.  
 
An “integrated” diagnostic approach alters the frequency of astrocytoma and 
oligodendroglioma diagnoses 
Up to WHO 2007, the frequency with which astrocytoma, oligoastrocytoma and oligodendroglioma 
were diagnosed demonstrated a great inter-institutional variation. Most of this variation was accounted 
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for by the use of the diagnosis oligoastrocytoma. Linking the definition of astrocytoma and 
oligodendroglioma more strongly to biological parameters and omitting the use of the diagnosis 
oligoastrocytoma will reduce this inter-institutional variation. In our own experience based on 
diagnoses from the Department of Neuropathology in Heidelberg, the major part of tumors formerly 
diagnosed oligoastrocytoma fall into the “integrated” diagnostic group of oligodendroglioma and 
approximately one third of all diffuse glioma are diagnosed as oligodendrogliomas whereas two thirds 
of diffuse glioma are diagnosed as astrocytomas. 
The integrated approach influences classification, it has less impact on grading of these tumors apart 
from anaplastic oligoastrocytomas which in our series sometimes were rediagnosed as OII and 
sometimes as OIII while amongst those rediagnosed as astrocytomas all were anaplastic. This 
underlines the concept that classification recognizes biological origin while grading reflects to a stage 
in tumor progression. 
 
Practical approach for diagnosing astrocytomas and oligodendrogliomas using the 
“integrated” approach 
The routine approach to all diffuse astrocytic and oligodendroglial gliomas begins with performing IHC 
for ATRX and IDH1-R132H expression. Almost all of the tumors exhibiting loss of nuclear ATRX 
staining are astrocytic. The majority of these tumors will stain positive for IDH1-R132H and nearly all 
of those which will not are subsequently found to harbor a rare IDH1 or IDH2 or a H3F3A mutation. In 
contrast, all tumors with nuclear ATRX expression are subjected to 1p/19q analysis. The tumors 
without a combined deletion of 1p/19q are astrocytic tumors, independent of their IDH status. This 
group should be sequenced for rare IDH1 and IDH2 mutations based on the important impact of IDH 
status on prognosis. Astrocytic tumors without ATRX loss, wild type for 1p/19q and without IDH 
mutation have a strong likelihood of being glioblastoma. Further molecular analyses such as 
determining 7p/10q status, EGFR or CDK4 amplification is useful. 
All tumors exhibiting 1p/19q loss are oligodendrogliomas. Oligodendrogliomas without IDH1-R132H 
positivity need not be sequenced for rare IDH mutations, which would almost certainly be detectable in 
all of them. A diagnostic scheme is provided in figure 7. 
 
Conclusions 
The present data provide an approach to build an “integrated diagnosis” for adult astrocytic and 
oligodendroglial glioma based on histology and molecular parameters. ATRX immunohistochemistry 
constitutes an important parameter for this approach. The “integrated” diagnosis results in stringent 
separation of astrocytoma from oligodendroglioma, omitting the need for diagnosing oligoastrocytoma 
or ‘glioblastoma with oligodendroglial component’. Stepwise analysis of the molecular parameters 
significantly reduces the number of molecular tests required for unequivocal diagnosis.  
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RX_REUNT_GESLTERSA tbl_WHO_CNS.txt_WHO_CNS
43516 m 29 Anaplastic astrocytoma (WHO grade III)
43846 m 36 Anaplastic astrocytoma (WHO grade III)
43868 m 74 Anaplastic astrocytoma (WHO grade III)
43726 m 53 Anaplastic oligoastrocytoma (WHO grade III)
43642 m 43 Anaplastic astrocytoma (WHO grade III)
57248 m 30 Anaplastic astrocytoma (WHO grade III)
41252 m 78 Anaplastic oligoastrocytoma (WHO grade III)
43690 f 31 Anaplastic astrocytoma (WHO grade III)
43878 m 61 Anaplastic oligoastrocytoma (WHO grade III)
43918 m 24 Anaplastic oligodendroglioma (WHO grade III)
43904 f 37 Anaplastic astrocytoma (WHO grade III)
43512 f 32 Anaplastic astrocytoma (WHO grade III)
43626 m 27 Anaplastic astrocytoma (WHO grade III)
48336 f 49 Anaplastic astrocytoma (WHO grade III)
43862 m 36 Anaplastic astrocytoma (WHO grade III)
48302 m 35 Anaplastic astrocytoma (WHO grade III)
43890 f 48 Anaplastic oligoastrocytoma (WHO grade III)
43906 m 30 Anaplastic astrocytoma (WHO grade III)
41546 f 44 Anaplastic astrocytoma (WHO grade III)
43914 m 28 Anaplastic oligoastrocytoma (WHO grade III)
43616 m 36 Anaplastic astrocytoma (WHO grade III)
43536 m 39 Anaplastic astrocytoma (WHO grade III)
43940 m 50 Anaplastic astrocytoma (WHO grade III)
43582 m 26 Anaplastic oligoastrocytoma (WHO grade III)
43580 m 55 Anaplastic oligodendroglioma (WHO grade III)
43912 m 33 Anaplastic astrocytoma (WHO grade III)
48324 f 37 Anaplastic astrocytoma (WHO grade III)
48332 m 69 Anaplastic astrocytoma (WHO grade III)
43620 m 32 Anaplastic oligoastrocytoma (WHO grade III)
43670 f 45 Anaplastic astrocytoma (WHO grade III)
43692 m 35 Anaplastic astrocytoma (WHO grade III)
43698 m 49 Anaplastic astrocytoma (WHO grade III)
41790 m 27 Anaplastic astrocytoma (WHO grade III)
43348 f 45 Anaplastic astrocytoma (WHO grade III)
43702 m 43 Anaplastic oligoastrocytoma (WHO grade III)
43864 f 42 Anaplastic oligoastrocytoma (WHO grade III)
43704 f 26 Anaplastic oligoastrocytoma (WHO grade III)
43858 m 39 Anaplastic astrocytoma (WHO grade III)
43478 m 38 Anaplastic oligoastrocytoma (WHO grade III)
43714 m 36 Anaplastic astrocytoma (WHO grade III)
43660 m 26 Anaplastic astrocytoma (WHO grade III)
43738 m 55 Anaplastic oligodendroglioma (WHO grade III)
43634 m 41 Anaplastic oligoastrocytoma (WHO grade III)
43484 m 33 Anaplastic astrocytoma (WHO grade III)
43488 f 32 Anaplastic astrocytoma (WHO grade III)
43756 m 53 Anaplastic astrocytoma (WHO grade III)
43796 f 35 Anaplastic astrocytoma (WHO grade III)
43826 m 30 Anaplastic astrocytoma (WHO grade III)
43824 m 39 Anaplastic astrocytoma (WHO grade III)
43732 f 45 Anaplastic astrocytoma (WHO grade III)
41590 m 42 Anaplastic oligoastrocytoma (WHO grade III)
41402 m 35 Anaplastic astrocytoma (WHO grade III)
43640 m 39 Anaplastic astrocytoma (WHO grade III)
60298 m 36 Anaplastic astrocytoma (WHO grade III)
47302 f 36 Anaplastic oligoastrocytoma (WHO grade III)
64768 m 41 Anaplastic astrocytoma (WHO grade III)
48224 f 28 Anaplastic astrocytoma (WHO grade III)
65926 m 60 Diffuse astrocytoma (WHO grade II)
48112 m 38 Anaplastic astrocytoma (WHO grade III)
66854 f 27 Anaplastic astrocytoma (WHO grade III)
45128 m 31 Anaplastic astrocytoma (WHO grade III)
41336 m 27 Anaplastic oligoastrocytoma (WHO grade III)
66294 m 23 Glioblastoma (WHO grade IV)
70862 f 32 Oligodendroglioma (WHO grade II)
67938 m 28 Anaplastic astrocytoma (WHO grade III)
70788 m 71 Anaplastic astrocytoma (WHO grade III)
69762 m 28 Anaplastic astrocytoma (WHO grade III)
68286 m 36 Anaplastic oligoastrocytoma (WHO grade III)
68566 m 32 Anaplastic astrocytoma (WHO grade III)
69570 f 31 Anaplastic astrocytoma (WHO grade III)
70052 f 21 Anaplastic astrocytoma (WHO grade III)
69196 m 46 Glioblastoma (WHO grade IV)
69192 m 47 Diffuse astrocytoma (WHO grade II)
70826 f 32 Anaplastic astrocytoma (WHO grade III)
68976 f 37 Anaplastic oligoastrocytoma (WHO grade III)
70050 f 43 Anaplastic astrocytoma (WHO grade III)
51058 m 33 Anaplastic astrocytoma (WHO grade III)
50782 m 30 Anaplastic astrocytoma (WHO grade III)
67628 f 34 Anaplastic astrocytoma (WHO grade III)
64262 f 52 Anaplastic astrocytoma (WHO grade III)
48584 m 62 Anaplastic astrocytoma (WHO grade III)
70422 m 45 Anaplastic oligoastrocytoma (WHO grade III)
70550 f 40 Oligoastrocytoma (WHO grade II)
68958 f 63 Anaplastic astrocytoma (WHO grade III)
61518 f 31 Anaplastic astrocytoma (WHO grade III)
67666 m 69 Anaplastic astrocytoma (WHO grade III)
70558 m 28 Anaplastic oligoastrocytoma (WHO grade III)
64010 m 20 Anaplastic astrocytoma (WHO grade III)
43632 f 46 Anaplastic oligoastrocytoma (WHO grade III)
60900 f 18 Anaplastic astrocytoma (WHO grade III)
43534 f 38 Anaplastic astrocytoma (WHO grade III)
59252 f 30 Anaplastic oligodendroglioma (WHO grade III)
42162 f 37 Anaplastic oligodendroglioma (WHO grade III)
48266 f 51 Anaplastic astrocytoma (WHO grade III)
69296 m 37 Anaplastic astrocytoma (WHO grade III)
43540 f 42 Anaplastic oligoastrocytoma (WHO grade III)
40642 f 39 Anaplastic astrocytoma (WHO grade III)
53022 m 36 Anaplastic astrocytoma (WHO grade III)
68026 f 49 Anaplastic astrocytoma (WHO grade III)
70332 m 31 Anaplastic oligoastrocytoma (WHO grade III)
56428 m 31 Anaplastic astrocytoma (WHO grade III)
22966 f 35 Anaplastic astrocytoma (WHO grade III)
43926 m 37 Anaplastic astrocytoma (WHO grade III)
70790 m 40 Anaplastic astrocytoma (WHO grade III)
57706 m 57 Anaplastic astrocytoma (WHO grade III)
43666 f 31 Anaplastic astrocytoma (WHO grade III)
59208 m 26 Anaplastic astrocytoma (WHO grade III)
48300 m 31 Anaplastic astrocytoma (WHO grade III)
42866 f 43 Anaplastic astrocytoma (WHO grade III)
48326 m 37 Anaplastic astrocytoma (WHO grade III)
50568 f 20 Anaplastic astrocytoma (WHO grade III)
51994 m 33 Oligoastrocytoma (WHO grade II)
43736 m 63 Anaplastic oligodendroglioma (WHO grade III)
43696 m 52 Anaplastic oligodendroglioma (WHO grade III)
43722 m 72 Anaplastic oligoastrocytoma (WHO grade III)
43578 m 43 Anaplastic oligoastrocytoma (WHO grade III)
43934 f 34 Anaplastic oligoastrocytoma (WHO grade III)
43628 f 53 Anaplastic oligoastrocytoma (WHO grade III)
45848 f 71 Glioblastoma with oligodendroglial differentiation (WHO 
43614 m 39 Anaplastic oligoastrocytoma (WHO grade III)
43884 m 60 Anaplastic astrocytoma (WHO grade III)
43542 m 50 Anaplastic oligoastrocytoma (WHO grade III)
22982 m 36 Anaplastic astrocytoma (WHO grade III)
33354 f 57 Glioblastoma with oligodendroglial differentiation (WHO 
68664 f 51 Glioblastoma (WHO grade IV)
68292 m 47 Glioblastoma secondary (WHO grade IV)
43564 m 37 Anaplastic oligodendroglioma (WHO grade III)
43566 m 53 Anaplastic oligoastrocytoma (WHO grade III)
43572 m 33 Anaplastic oligodendroglioma (WHO grade III)
43612 f 41 Anaplastic oligodendroglioma (WHO grade III)
42626 m 62 Anaplastic oligodendroglioma (WHO grade III)
43482 m 44 Anaplastic oligoastrocytoma (WHO grade III)
43638 f 35 Anaplastic oligodendroglioma (WHO grade III)
43576 m 56 Anaplastic oligoastrocytoma (WHO grade III)
43654 f 47 Anaplastic oligoastrocytoma (WHO grade III)
43630 f 64 Anaplastic oligoastrocytoma (WHO grade III)
43648 f 65 Anaplastic oligoastrocytoma (WHO grade III)
43490 f 35 Anaplastic oligodendroglioma (WHO grade III)
43528 m 42 Anaplastic oligoastrocytoma (WHO grade III)
43880 m 41 Anaplastic oligodendroglioma (WHO grade III)
50060 f 49 Anaplastic oligodendroglioma (WHO grade III)
43920 f 55 Anaplastic oligoastrocytoma (WHO grade III)
43910 m 57 Anaplastic oligoastrocytoma (WHO grade III)
43908 f 53 Anaplastic oligoastrocytoma (WHO grade III)
43882 f 41 Anaplastic oligoastrocytoma (WHO grade III)
43816 f 61 Anaplastic oligoastrocytoma (WHO grade III)
43814 m 40 Anaplastic astrocytoma (WHO grade III)
43710 m 51 Anaplastic oligoastrocytoma (WHO grade III)
43794 m 39 Anaplastic oligodendroglioma (WHO grade III)
43750 m 58 Anaplastic oligoastrocytoma (WHO grade III)
43708 m 39 Anaplastic oligodendroglioma (WHO grade III)
43802 f 61 Anaplastic oligodendroglioma (WHO grade III)
43688 f 53 Anaplastic oligoastrocytoma (WHO grade III)
48460 m 38 Anaplastic oligodendroglioma (WHO grade III)
41486 m 47 Anaplastic oligoastrocytoma (WHO grade III)
43134 m 43 Glioblastoma with oligodendroglial differentiation (WHO 
58462 f 45 Anaplastic oligoastrocytoma (WHO grade III)
55292 f 43 Anaplastic oligodendroglioma (WHO grade III)
68660 m 50 Anaplastic oligodendroglioma (WHO grade III)
70176 m 45 Oligodendroglioma (WHO grade II)
67720 m 54 Anaplastic oligoastrocytoma (WHO grade III)
67912 f 43 Oligodendroglioma (WHO grade II)
70606 f 60 Glioblastoma with oligodendroglial differentiation (WHO 
68130 m 42 Anaplastic oligodendroglioma (WHO grade III)
55576 m 40 Anaplastic oligodendroglioma (WHO grade III)
67020 f 63 Anaplastic oligodendroglioma (WHO grade III)
71254 m 35 Anaplastic oligoastrocytoma (WHO grade III)
53286 f 46 Anaplastic oligodendroglioma (WHO grade III)
67034 m 60 Oligodendroglioma (WHO grade II)
62352 m 40 Anaplastic oligodendroglioma (WHO grade III)
49074 m 43 Anaplastic oligodendroglioma (WHO grade III)
64924 m 37 Anaplastic oligodendroglioma (WHO grade III)
67664 f 44 Anaplastic oligoastrocytoma (WHO grade III)
44826 f 45 Anaplastic oligodendroglioma (WHO grade III)
57250 m 61 Anaplastic oligodendroglioma (WHO grade III)
54736 m 72 Glioblastoma secondary (WHO grade IV)
67266 m 56 Anaplastic oligoastrocytoma (WHO grade III)
41196 m 31 Glioblastoma secondary (WHO grade IV)
57152 f 29 Anaplastic oligodendroglioma (WHO grade III)
43728 f 55 Anaplastic oligodendroglioma (WHO grade III)
43760 m 35 Anaplastic oligoastrocytoma (WHO grade III)
56604 f 66 Anaplastic oligodendroglioma (WHO grade III)
43574 f 39 Anaplastic oligoastrocytoma (WHO grade III)
63314 m 40 Anaplastic oligoastrocytoma (WHO grade III)
57142 f 48 Anaplastic oligodendroglioma (WHO grade III)
64466 f 67 Diffuse astrocytoma (WHO grade II)
40302 m 50 Diffuse astrocytoma (WHO grade II)
64446 f 30 Diffuse astrocytoma (WHO grade II)
67634 f 31 Diffuse astrocytoma (WHO grade II)
60272 m 69 Diffuse astrocytoma (WHO grade II)
49584 m 32 Diffuse astrocytoma (WHO grade II)
48298 m 24 Diffuse astrocytoma (WHO grade II)
48304 f 38 Diffuse astrocytoma (WHO grade II)
48320 f 23 Diffuse astrocytoma (WHO grade II)
43250 f 51 Diffuse astrocytoma (WHO grade II)
64442 m 59 Diffuse astrocytoma (WHO grade II)
68662 m 31 Diffuse astrocytoma (WHO grade II)
48198 f 27 Diffuse astrocytoma (WHO grade II)
44692 m 26 Diffuse astrocytoma (WHO grade II)
49748 f 52 Diffuse astrocytoma (WHO grade II)
67754 f 31 Diffuse astrocytoma (WHO grade II)
67742 m 43 Oligodendroglioma (WHO grade II)
41532 f 40 Diffuse astrocytoma (WHO grade II)
69864 m 37 Diffuse astrocytoma (WHO grade II)
65240 m 40 Diffuse astrocytoma (WHO grade II)
61058 f 26 Diffuse astrocytoma (WHO grade II)
48570 f 54 Diffuse astrocytoma (WHO grade II)
60242 m 37 Diffuse astrocytoma (WHO grade II)
58794 m 46 Diffuse astrocytoma (WHO grade II)
66860 f 38 Diffuse astrocytoma (WHO grade II)
52044 f 30 Diffuse astrocytoma (WHO grade II)
66930 m 30 Oligoastrocytoma (WHO grade II)
65316 f 29 Diffuse astrocytoma (WHO grade II)
68042 m 59 Diffuse astrocytoma (WHO grade II)
67744 f 26 Diffuse astrocytoma (WHO grade II)
70426 f 31 Oligoastrocytoma (WHO grade II)
69630 f 41 Diffuse astrocytoma (WHO grade II)
69216 m 29 Diffuse astrocytoma (WHO grade II)
71050 m 25 Diffuse astrocytoma (WHO grade II)
69704 f 40 Diffuse astrocytoma (WHO grade II)
70424 m 51 Oligoastrocytoma (WHO grade II)
69056 f 29 Diffuse astrocytoma (WHO grade II)
70756 m 49 Diffuse astrocytoma (WHO grade II)
54508 m 38 Diffuse astrocytoma (WHO grade II)
69194 m 26 Diffuse astrocytoma (WHO grade II)
51874 f 28 Diffuse astrocytoma (WHO grade II)
60234 m 42 Oligodendroglioma (WHO grade II)
64962 f 72 Giant cell glioblastoma (WHO grade IV)
64898 f 84 Giant cell glioblastoma (WHO grade IV)
59770 f 59 Giant cell glioblastoma (WHO grade IV)
68084 m 49 Glioblastoma (WHO grade IV)
43894 f 71 Anaplastic astrocytoma (WHO grade III)
71186 f 57 Glioblastoma (WHO grade IV)
70932 m 60 Glioblastoma (WHO grade IV)
53266 m 49 Anaplastic astrocytoma (WHO grade III)
68424 m 71 Glioblastoma (WHO grade IV)
56182 m 46 Anaplastic astrocytoma (WHO grade III)
69006 f 40 Glioblastoma (WHO grade IV)
58286 m 55 Anaplastic astrocytoma (WHO grade III)
51136 m 37 Anaplastic astrocytoma (WHO grade III)
64794 f 61 Diffuse astrocytoma (WHO grade II)
69686 m 62 Glioblastoma (WHO grade IV)
58450 f 59 Anaplastic astrocytoma (WHO grade III)
50446 f 59 Glioblastoma (WHO grade IV)
43844 f 58 Anaplastic oligoastrocytoma (WHO grade III)
44814 f 76 Anaplastic astrocytoma (WHO grade III)
43916 f 55 Anaplastic astrocytoma (WHO grade III)
28166 m 68 Anaplastic astrocytoma (WHO grade III)
43892 m 40 Anaplastic astrocytoma (WHO grade III)
48192 f 49 Diffuse astrocytoma (WHO grade II)
43842 m 41 Anaplastic astrocytoma (WHO grade III)
65616 f 64 Anaplastic astrocytoma (WHO grade III)
43830 m 62 Anaplastic astrocytoma (WHO grade III)
43748 f 59 Anaplastic astrocytoma (WHO grade III)
43712 m 64 Anaplastic astrocytoma (WHO grade III)
43636 m 56 Anaplastic astrocytoma (WHO grade III)
65230 f 70 Anaplastic astrocytoma (WHO grade III)
43550 m 64 Anaplastic astrocytoma (WHO grade III)
43496 f 60 Anaplastic astrocytoma (WHO grade III)
41588 m 67 Glioblastoma with oligodendroglial differentiation (WHO 
51086 m 39 Anaplastic astrocytoma (WHO grade III)
60608 m 51 Anaplastic astrocytoma (WHO grade III)
41496 f 59 Anaplastic oligodendroglioma (WHO grade III)
49144 m 59 Glioblastoma (WHO grade IV)
61050 f 52 Anaplastic astrocytoma (WHO grade III)
70126 m 82 Glioblastoma (WHO grade IV)
69548 m 76 Glioblastoma (WHO grade IV)
69542 m 79 Glioblastoma (WHO grade IV)
69540 m 71 Glioblastoma (WHO grade IV)
69626 m 64 Glioblastoma (WHO grade IV)
69352 m 71 Glioblastoma (WHO grade IV)
70128 f 43 Glioblastoma (WHO grade IV)
69354 f 37 Glioblastoma (WHO grade IV)
67106 f 54 Glioblastoma (WHO grade IV)
54426 f 81 Glioblastoma (WHO grade IV)
67104 f 58 Diffuse astrocytoma (WHO grade II)
67102 m 64 Glioblastoma (WHO grade IV)
69972 m 55 Glioblastoma (WHO grade IV)
69830 m 84 Glioblastoma (WHO grade IV)
69862 m 75 Glioblastoma (WHO grade IV)
71236 f 60 Glioblastoma (WHO grade IV)
69896 f 58 Glioblastoma (WHO grade IV)
67004 m 71 Glioblastoma (WHO grade IV)
69652 f 66 Glioblastoma (WHO grade IV)
68446 f 72 Glioblastoma (WHO grade IV)
67722 m 48 Glioblastoma (WHO grade IV)
71082 f 78 Diffuse astrocytoma (WHO grade II)
68090 f 64 Glioblastoma (WHO grade IV)
70612 m 59 Glioblastoma (WHO grade IV)
67548 f 50 Glioblastoma (WHO grade IV)
70568 m 53 Glioblastoma (WHO grade IV)
70548 m 54 Glioblastoma (WHO grade IV)
71146 f 73 Glioblastoma (WHO grade IV)
69122 m 66 Glioblastoma (WHO grade IV)
68440 f 52 Glioblastoma (WHO grade IV)
70130 m 66 Glioblastoma (WHO grade IV)
68490 m 42 Glioblastoma (WHO grade IV)
69814 m 63 Glioblastoma (WHO grade IV)
55502 f 76 Glioblastoma with oligodendroglial differentiation (WHO 
66908 f 65 Glioblastoma (WHO grade IV)
40144 f 77 Glioblastoma with oligodendroglial differentiation (WHO 
70376 m 61 Glioblastoma (WHO grade IV)
69004 m 60 Glioblastoma (WHO grade IV)
41568 m 37 Glioblastoma (WHO grade IV)
70170 f 64 Glioblastoma (WHO grade IV)
68430 f 76 Anaplastic astrocytoma (WHO grade III)
66532 m 60 Glioblastoma (WHO grade IV)
60250 m 66 Glioblastoma (WHO grade IV)
59272 m 76 Glioblastoma (WHO grade IV)
66480 f 84 Glioblastoma (WHO grade IV)
66304 m 38 Glioblastoma (WHO grade IV)
64146 m 63 Glioblastoma (WHO grade IV)
64380 m 47 Glioblastoma (WHO grade IV)
57836 f 62 Glioblastoma (WHO grade IV)
65228 f 73 Glioblastoma (WHO grade IV)
63936 f 46 Glioblastoma with oligodendroglial differentiation (WHO 
66768 m 52 Glioblastoma (WHO grade IV)
51804 f 73 Glioblastoma (WHO grade IV)
64756 m 76 Glioblastoma (WHO grade IV)
66906 f 81 Glioblastoma (WHO grade IV)
65052 f 57 Glioblastoma (WHO grade IV)
66646 f 81 Glioblastoma (WHO grade IV)
64416 m 78 Glioblastoma (WHO grade IV)
27920 m 51 Anaplastic astrocytoma (WHO grade III)
57222 m 39 Glioblastoma (WHO grade IV)
50040 m 59 Glioblastoma with oligodendroglial differentiation (WHO 
68046 m 42 Glioblastoma (WHO grade IV)
43388 f 34 Anaplastic oligodendroglioma (WHO grade III)
53262 f 64 Glioblastoma with oligodendroglial differentiation (WHO 
65800 m 82 Glioblastoma (WHO grade IV)
69770 f 76 Glioblastoma (WHO grade IV)
53252 m 42 Glioblastoma (WHO grade IV)
65208 m 57 Glioblastoma (WHO grade IV)
67132 m 27 Glioblastoma (WHO grade IV)
63930 f 60 Glioblastoma (WHO grade IV)
69822 m 25 Glioblastoma (WHO grade IV)
51054 m 73 Glioblastoma (WHO grade IV)
57834 m 62 Glioblastoma (WHO grade IV)
66728 m 69 Glioblastoma (WHO grade IV)
51988 m 20 Glioblastoma (WHO grade IV)
61454 f 21 Glioblastoma (WHO grade IV)
68510 m 27 Glioblastoma (WHO grade IV)
67620 f 31 Glioblastoma (WHO grade IV)
65086 m 32 Glioblastoma (WHO grade IV)
69710 f 51 Glioblastoma (WHO grade IV)
61428 f 19 Glioblastoma (WHO grade IV)
69950 f 74 Glioblastoma (WHO grade IV)
64428 m 51 Glioblastoma (WHO grade IV)
63934 f 54 Glioblastoma with oligodendroglial differentiation (WHO 
70328 f 44 Glioblastoma (WHO grade IV)
50610 f 33 Glioblastoma (WHO grade IV)
40922 m 57 Glioblastoma (WHO grade IV)
67642 m 34 Glioblastoma secondary (WHO grade IV)
67648 m 47 Glioblastoma secondary (WHO grade IV)
51926 f 55 Glioblastoma (WHO grade IV)
67662 f 55 Glioblastoma secondary (WHO grade IV)
71180 m 38 Glioblastoma (WHO grade IV)
53298 m 28 Glioblastoma secondary (WHO grade IV)
68460 f 35 Glioblastoma (WHO grade IV)
60910 f 22 Glioblastoma (WHO grade IV)
70640 f 49 Glioblastoma (WHO grade IV)
59352 m 52 Glioblastoma with oligodendroglial differentiation (WHO 
41148 m 60 Glioblastoma (WHO grade IV)
60162 f 76 Gliosarcoma (WHO grade IV)
52180 f 64 Gliosarcoma (WHO grade IV)
59486 m 72 Gliosarcoma (WHO grade IV)
59774 f 59 Gliosarcoma (WHO grade IV)
64080 m 64 Gliosarcoma (WHO grade IV)
60236 f 71 Gliosarcoma (WHO grade IV)
64764 m 80 Gliosarcoma (WHO grade IV)
60166 f 75 Gliosarcoma (WHO grade IV)
40824 m 60 Gliosarcoma (WHO grade IV)
64870 m 79 Gliosarcoma (WHO grade IV)
58154 m 37 Gliosarcoma (WHO grade IV)
60164 m 46 Gliosarcoma (WHO grade IV)
60246 m 51 Gliosarcoma (WHO grade IV)
60238 m 63 Gliosarcoma (WHO grade IV)
69298 m 31 Oligodendroglioma (WHO grade II)
69688 m 26 Diffuse astrocytoma (WHO grade II)
69946 m 18 Diffuse astrocytoma (WHO grade II)
64890 f 54 Oligodendroglioma (WHO grade II)
46306 m 18 Oligodendroglioma (WHO grade II)
68536 f 33 Oligodendroglioma (WHO grade II)
64084 m 49 Oligodendroglioma (WHO grade II)
66770 m 40 Oligodendroglioma (WHO grade II)
50254 m 42 Oligodendroglioma (WHO grade II)
67756 m 49 Diffuse astrocytoma (WHO grade II)
67144 f 48 Oligodendroglioma (WHO grade II)
64488 m 32 Oligodendroglioma (WHO grade II)
69564 m 28 Oligodendroglioma (WHO grade II)
70382 m 78 Oligodendroglioma (WHO grade II)
69708 f 66 Oligodendroglioma (WHO grade II)
60474 f 32 Oligodendroglioma (WHO grade II)
68426 m 53 Oligodendroglioma (WHO grade II)
65662 f 74 Oligoastrocytoma (WHO grade II)
68576 m 42 Diffuse astrocytoma (WHO grade II)
70644 f 31 Anaplastic oligoastrocytoma (WHO grade III)
63990 m 30 Oligodendroglioma (WHO grade II)
70860 m 62 Oligodendroglioma (WHO grade II)
69816 m 33 Oligodendroglioma (WHO grade II)
57584 f 20 Oligoastrocytoma (WHO grade II)
57760 m 49 Oligodendroglioma (WHO grade II)
55958 f 25 Oligoastrocytoma (WHO grade II)
56172 m 51 Oligodendroglioma (WHO grade II)
56878 f 70 Oligoastrocytoma (WHO grade II)
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Astrozytom IDH mut Anaplastic ex4 wt ex4 wt
Astrozytom IDH mut Anaplastic ex4 wt wdh ex4 wt
Glioblastom Anaplastic ex4 wt ex4 wt
Glioblastom Anaplastic ex4 wt ex4 wt
Glioblastom Anaplastic ex4 wt ex4 wt
Gliom H3.3 K27 mut Anaplastic ex4 wt ex4 wt
Gliom H3.3 K27 mut Anaplastic ex4 wt ex4 wt
Gliom H3.3 K27 mut Anaplastic ex4 wt ex4 wt
Gliom H3.3 K27 mut Anaplastic ex4 wt ex4 wt
Gliom H3.3 K27 mut Anaplastic ex4 wt ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H
Astrozytom IDH mut Anaplastic R132H
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic R132S ex4 wt
Astrozytom IDH mut Anaplastic R132S ex4 wt
Astrozytom IDH mut Anaplastic R132S ex4 wt
Astrozytom IDH mut Anaplastic R132S ex4 ND
Astrozytom IDH mut Anaplastic R132S ex4 ND
Astrozytom IDH mut Anaplastic R132G ex4 wt
Astrozytom IDH mut Anaplastic R132G ex4 wt
Astrozytom IDH mut Anaplastic R132G ex4 wt
Astrozytom IDH mut Anaplastic R132G ex4 wt
Astrozytom IDH mut Anaplastic R132G ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C ex4 wt
Astrozytom IDH mut Anaplastic R132C
Astrozytom IDH mut Anaplastic ex4 wt R172K
Glioblastom Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H ex4 wt
Astrozytom IDH mut Anaplastic R132H
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Astrozytom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H ex4 wt
Oligodendrogliom IDH mut Anaplastic R132H
Oligodendrogliom IDH mut Anaplastic R132H
Oligodendrogliom IDH mut Anaplastic R132H
Oligodendrogliom IDH mut Anaplastic ex4 wt
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic 
Oligodendrogliom IDH mut Anaplastic R132S ex4 wt
Oligodendrogliom IDH mut Anaplastic R132L ex4 wt
Oligodendrogliom IDH mut Anaplastic R132L ex4 wt
Oligodendrogliom IDH mut Anaplastic R132L ex4 wt
Oligodendrogliom IDH mut Anaplastic R132G ex4 wt
Oligodendrogliom IDH mut Anaplastic R132C ex4 wt
Oligodendrogliom IDH mut Anaplastic R132C ex4 wt
Oligodendrogliom IDH mut Anaplastic ex4 wt R172W
Oligodendrogliom IDH mut Anaplastic ex4 wt R172K
Oligodendrogliom IDH mut Anaplastic ex4 wt R172K
Oligodendrogliom IDH mut Anaplastic ex4 wt R172K
Oligodendrogliom IDH mut Anaplastic R172K
Astrozytom IDH mut Diffuse ex4 wt wdh ex4 wt wdh
Astrozytom IDH mut Diffuse ex4 wt ex4 wt
Astrozytom IDH mut Diffuse ex4 wt
Astrozytom IDH mut Diffuse ex4 G105G ex4 wt
Glioblastom Diffuse ex4 wt ex4 wt
Astrozytom IDH mut Diffuse R132H ex4 wt
Astrozytom IDH mut Diffuse R132H ex4 wt
Astrozytom IDH mut Diffuse R132H ex4 wt
Astrozytom IDH mut Diffuse R132H ex4 wt
Astrozytom IDH mut Diffuse R132H ex4 wt
Astrozytom IDH mut Diffuse R132H ex4 wt
Astrozytom IDH mut Diffuse R132H ex4 wt
Astrozytom IDH mut Diffuse R132H ex4 wt
Astrozytom IDH mut Diffuse R132H
Astrozytom IDH mut Diffuse R132H
Astrozytom IDH mut Diffuse R132H
Astrozytom IDH mut Diffuse R132H
Astrozytom IDH mut Diffuse R132H
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse 
Astrozytom IDH mut Diffuse R132G ex4 wt
Astrozytom IDH mut Diffuse R132C ex4 wt
Astrozytom IDH mut Diffuse R132C ex4 wt
Astrozytom IDH mut Diffuse R132C
Glioblastom Giant cell 
Glioblastom Giant cell 
Glioblastom Giant cell 
Astrozytom IDH mut Glioblastoma G105G ex4 wt
Astrozytom IDH mut Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt ex4 wt
Glioblastom Glioblastoma ex4 wt
Glioblastom Glioblastoma ex4 wt
Glioblastom Glioblastoma ex4 wt
Glioblastom Glioblastoma ex4 wt
Glioblastom Glioblastoma ex4 wt
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom Glioblastoma 
Glioblastom RTK1 Glioblastoma ex4 wt ex4 wt
Glioblastom RTK1 Glioblastoma ex4 wt ex4 wt
Glioblastom RTK1 Glioblastoma ex4 wt ex4 wt
Glioblastom RTK1 Glioblastoma ex4 wt ex4 wt
Glioblastom RTK1 Glioblastoma ex4 wt ex4 wt
Glioblastom RTK1 Glioblastoma ex4 wt ex4 wt
Glioblastom RTK1 Glioblastoma ex4 wt
Glioblastom RTK1 Glioblastoma 
Glioblastom RTK1 Glioblastoma 
Glioblastom RTK1 Glioblastoma 
Glioblastom RTK1 Glioblastoma 
Glioblastom RTK1 Glioblastoma 
Glioblastom RTK1 Glioblastoma 
Glioblastom RTK1 Glioblastoma 
Glioblastom RTK1 Glioblastoma 
Glioblastom RTK1 Glioblastoma 
Gliom H3.3 G34 mut Glioblastoma ex4 wt ex4 wt
Gliom H3.3 G34 mut Glioblastoma ex4 wt ex4 wt
Gliom H3.3 G34 mut Glioblastoma ex4 wt ex4 wt
Gliom H3.3 G34 mut Glioblastoma 
Gliom H3.3 K27 mut Glioblastoma ex4 wt ex4 wt
Gliom H3.3 K27 mut Glioblastoma ex4 wt ex4 wt
Gliom H3.3 K27 mut Glioblastoma ex4 wt
Gliom H3.3 K27 mut Glioblastoma 
Gliom H3.3 K27 mut Glioblastoma 
Gliom H3.3 K27 mut Glioblastoma 
Astrozytom IDH mut Glioblastoma R132H ex4 wt
Astrozytom IDH mut Glioblastoma R132H ex4 wt
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma 
Astrozytom IDH mut Glioblastoma R132G ex4 wt
Astrozytom IDH mut Glioblastoma ex4 wt R172G
Glioblastom Gliosarcoma ex4 wt ex4 wt
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Glioblastom Gliosarcoma 
Maligner peripherer Nervenscheidentumor Gliosarcoma 
Maligner peripherer Nervenscheidentumor Gliosarcoma 
Astrozytom IDH mut Oligodendroglio
Astrozytom IDH mut Oligodendroglio
Astrozytom IDH mut Oligodendroglio
Astrozytom IDH mut Oligodendroglio
Astrozytom IDH mut Oligodendroglio
Astrozytom IDH mut Oligodendroglio ex4 wt R172K
Oligodendrogliom IDH mut Oligodendroglio R132H ex4 wt
Oligodendrogliom IDH mut Oligodendroglio R132H ex4 wt
Oligodendrogliom IDH mut Oligodendroglio R132H
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio
Oligodendrogliom IDH mut Oligodendroglio ex4 wt R172K
Oligodendrogliom IDH mut Oligodendroglio ex4 wt R172K
Oligodendrogliom IDH mut Oligodendroglio ex4 wt R172K
Oligodendrogliom IDH mut Oligodendroglio R172K
Oligodendrogliom IDH mut Oligodendroglio R172K
h3f3a tert 1p 19q 7p 10q
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced het-del
in UTR wt balanced balanced gain balanced
-124 ATG (C228T) balanced balanced balanced balanced
K27M in UTR wt balanced balanced gain segmental balanced
ex3 wt in UTR wt balanced balanced balanced balanced
K27M in UTR wt het-del balanced balanced het-del
ex3 wt in UTR wt balanced het-del balanced balanced
ex3 wt in UTR wt balanced balanced gain balanced
in UTR wt balanced het-del balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced het-del
in UTR wt balanced het-del balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced het-del
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced het-del
in UTR wt balanced balanced balanced balanced
in UTR wt balanced het-del balanced balanced
in UTR wt balanced balanced balanced het-del
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt het-del het-del balanced balanced
in UTR wt balanced het-del gain balanced
in UTR wt balanced balanced gain balanced
in UTR wt balanced het-del balanced balanced
in UTR wt gain segmental gain balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced het-del balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced gain balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced het-del 
in UTR wt balanced het-del balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
ND balanced balanced balanced het-del 
in UTR wt balanced balanced balanced het-del 
in UTR wt balanced balanced gain balanced
int UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt het-del het-del gain complex
in UTR wt balanced het-del gain balanced
in UTR wt balanced het-del balanced balanced
in UTR wt balanced het-del gain balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
balanced balanced balanced balanced
balanced balanced balanced balanced
ND balanced balanced gain balanced
balanced het-del balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
balanced balanced balanced balanced
balanced balanced balanced balanced
balanced balanced balanced balanced
balanced balanced balanced balanced
gain segmental balanced balanced balanced
balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
balanced balanced balanced balanced
balanced balanced balanced balanced
in UTR wt balanced balanced gain balanced
balanced balanced balanced het-del 
in UTR wt het-del het-del balanced het-del 
balanced balanced balanced balanced
in UTR wt balanced balanced balanced het-del 
in UTR wt balanced het-del balanced het-del 
-146 ATG (C250T) balanced balanced balanced balanced
balanced balanced balanced balanced
balanced balanced balanced balanced
balanced het-del balanced balanced
balanced balanced balanced balanced
in UTR ND balanced balanced balanced balanced
in UTR wt balanced het-del het-del balanced
het-del het-del balanced balanced
gain complex balanced het-del 
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced gain balanced
ex3 wt in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
ex3 wt in UTR wt balanced balanced balanced het-del
ex3 wt in UTR wt balanced balanced balanced het-del
gain segmental balanced gain balanced
balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR ND balanced balanced balanced balanced
balanced balanced balanced het-del 
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
balanced balanced balanced balanced
in UTR wt balanced het-del balanced het-del 
in UTR wt balanced balanced het-del balanced
ex3 wt in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
ex3 wt in UTR wt balanced balanced balanced balanced
in UTR ND balanced balanced balanced balanced
in UTR wt balanced balanced balanced het-del
-124 ATG (C228T) het-del het-del balanced balanced
in UTR wt het-del het-del balanced het-del 
-124 ATG (C228T) het-del het-del balanced balanced
in UTR wt het-del het-del balanced balanced
in UTR wt het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
in UTR wt het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
ex3 wt -124 ATG (C228T) het-del het-del balanced balanced
het-del het-del balanced balanced
het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del gain balanced
-146 ATG (C250T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del gain balanced
-124 ATG (C228T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del gain balanced
in UTR wt het-del het-del balanced balanced
in UTR wt het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced het-del
-124 ATG (C228T) het-del het-del balanced balanced
het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
in UTR wt het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
in UTR wt het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del gain het-del
in UTR wt het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
ND het-del het-del balanced balanced
het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
in UTR ND het-del het-del balanced balanced
het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del gain balanced
-146 ATG (C250T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del het-del balanced
-146 ATG (C250T) het-del het-del balanced balanced
het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
ex3 wt -124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced het-del 
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
balanced balanced balanced balanced
balanced het-del balanced balanced
balanced balanced balanced balanced
in UTR ND balanced balanced balanced balanced
-124 ATG (C228T) balanced balanced gain het-del
in UTR wt balanced het-del balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR ND balanced het-del balanced balanced
in UTR wt balanced het-del balanced balanced
in UTR wt balanced het-del gain balanced
balanced het-del balanced balanced
balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR ND balanced balanced balanced balanced
in UTR wt balanced balanced gain segmental balanced
in UTR wt balanced balanced balanced balanced
ND balanced balanced gain het-del 
in UTR wt balanced het-del balanced balanced
in UTR ND balanced balanced gain balanced
balanced balanced balanced balanced
in UTR wt balanced het-del balanced het-del 
in UTR wt balanced het-del balanced balanced
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
balanced balanced balanced balanced
in UTR wt balanced balanced gain gain segmental
balanced balanced balanced het-del 
in UTR wt balanced balanced balanced balanced
balanced balanced balanced balanced
balanced balanced gain balanced
in UTR wt balanced balanced balanced balanced
balanced het-del balanced balanced
in UTR wt balanced balanced balanced balanced
balanced het-del balanced balanced
ND balanced balanced balanced het-del 
balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
balanced balanced balanced balanced
in UTR ND balanced balanced balanced balanced
in UTR wt balanced balanced balanced balanced
-124 ATG (C228T) balanced het-del gain het-del
in UTR ND balanced balanced gain het-del
-146 ATG (C250T) balanced balanced gain het-del
ex3 wt -124 ATG (C228T) balanced balanced balanced balanced
-146 ATG (C250T) het-del het-del gain het-del
het-del gain gain het-del
ex3 wt balanced gain gain balanced
-124 ATG (C228T) balanced gain gain het-del
-124 ATG (C228T) balanced gain segmental gain het-del
-124 ATG (C228T) het-del balanced gain het-del
ex3 wt balanced gain gain het-del
-124 ATG (C228T) balanced balanced gain balanced
-124 ATG (C228T) balanced balanced gain het-del
balanced balanced gain het-del
balanced balanced gain het-del
-124 ATG (C228T) het-del balanced gain het-del
-146 ATG (C250T) balanced balanced gain het-del
-146 ATG (C250T) balanced balanced gain het-del
-124 ATG (C228T) het-del het-del gain het-del
in UTR wt balanced balanced gain het-del
in UTR wt balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
int UTR wt het-del balanced balanced het-del
-124 ATG (C228T) balanced het-del gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced gain gain het-del
in UTR wt balanced balanced gain het-del
in UTR wt balanced balanced gain het-del
-124 ATG (C228T) balanced gain gain het-del
-124 ATG (C228T) balanced balanced gain balanced
-124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
in UTR wt balanced balanced gain het-del
balanced balanced gain het-del
balanced gain balanced het-del
balanced gain gain het-del
het-del balanced gain het-del
balanced balanced gain het-del
het-del balanced gain het-del
balanced balanced gain het-del
balanced gain balanced het-del
-124 ATG (C228T) het-del balanced balanced balanced
-124 ATG (C228T) balanced gain gain het-del
in UTR ND balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del 
balanced gain gain balanced
balanced het-del gain het-del
balanced gain gain balanced
balanced complex gain segmental het-del
balanced gain gain het-del
-146 ATG (C250T) balanced balanced gain het-del
balanced balanced gain het-del
in UTR ND balanced gain gain het-del
in UTR ND balanced balanced balanced het-del
balanced gain gain het-del
in UTR ND balanced balanced gain het-del
balanced balanced gain het-del
-124 ATG (C228T) balanced gain gain het-del 
het-del gain gain het-del
balanced balanced gain het-del
balanced gain gain het-del
-124 ATG (C228T) balanced balanced gain het-del
in UTR wt balanced gain gain het-del
balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
balanced balanced gain balanced
ex3 wt -146 ATG (C250T) balanced het-del gain het-del
-124 ATG (C228T) balanced gain gain het-del
ex3 wt in UTR wt balanced gain gain het-del
-146ATG balanced balanced gain het-del
-124 ATG (C228T) het-del balanced balanced het-del
in UTR wt balanced het-del balanced het-del
balanced balanced gain het-del
het-del gain gain het-del
-124 ATG (C228T) balanced gain gain het-del
-124 ATG (C228T) balanced gain gain balanced
-146 ATG (C250T) balanced balanced gain het-del
-124 ATG (C228T) balanced gain gain het-del
-124 ATG (C228T) balanced gain gain het-del
ex3 wt -146 ATG (C250T) balanced gain gain balanced
ex3 wt -124 ATG (C228T) balanced gain gain het-del
ex3 wt -124 ATG (C228T) het-del balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
ex3 wt in UTR wt amp gain gain het-del
-146 ATG (C250T) balanced balanced balanced het-del
ex3 wt -124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced gain gain het-del
-124 ATG (C228T) balanced gain gain balanced
-124 ATG (C228T) balanced gain gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-146 ATG (C250T) balanced balanced balanced het-del
-124 ATG (C228T) balanced balanced balanced het-del
ex3 wt in UTR wt balanced balanced gain het-del 
ex3 wt -124 ATG (C228T) balanced balanced balanced het-del
ex3 wt in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced het-del
in UTR wt het-del balanced gain het-del
-124 ATG (C228T) balanced gain gain het-del
balanced balanced gain het-del
ex3 wt in UTR wt het-del het-del balanced balanced
-124 C228T het-del balanced gain het-del
balanced het-del gain balanced
ex3 wt -124 ATG (C228T) balanced balanced balanced balanced
balanced balanced balanced het-del
ex3 wt -146 ATG (C250T) gain het-del gain het-del
ex3 wt -124 ATG (C228T) gain balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
G34R in UTR wt balanced balanced balanced het-del
G34R in UTR wt balanced balanced balanced het-del
G34R balanced balanced gain segmental het-del
G34R balanced balanced balanced het-del
ex3 wt in UTR ND balanced balanced het-del balanced
K27M balanced het-del balanced balanced
K27M in UTR wt balanced balanced balanced het-del 
ex3 wt balanced balanced balanced balanced
K27M in UTR wt balanced balanced balanced het-del
K27M in UTR wt balanced balanced balanced het-del 
balanced het-del balanced het-del
in UTR wt balanced het-del balanced het-del
in UTR ND balanced balanced balanced het-del
in UTR wt balanced balanced balanced balanced
in UTR wt balanced balanced balanced het-del
-124 ATG (C228T) balanced balanced balanced het-del
balanced het-del complex balanced
balanced het-del balanced het-del
ex3 wt in UTR wt het-del het-del balanced balanced
in UTR wt balanced balanced balanced het-del
in UTR wt balanced balanced balanced balanced
balanced balanced gain het-del 
in UTR wt balanced gain balanced het-del
in UTR wt balanced balanced balanced balanced
ex3 wt -124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced gain gain het-del
-146 ATG (C250T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-146 ATG (C250T) gain balanced balanced balanced
ex3 wt -124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
in UTR wt balanced balanced gain het-del
-124 ATG (C228T) balanced balanced gain het-del
ex3 wt -124 ATG (C228T) balanced balanced gain het-del
-146 ATG (C250T) balanced het-del gain het-del
-124 ATG (C228T) het-del balanced gain het-del
-146 ATG (C250T) het-del het-del balanced balanced
het-del het-del balanced balanced
het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
in UTR ND het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
ex3 wt -146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
het-del het-del balanced balanced
het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced het-del 
-124 ATG (C228T) het-del het-del balanced balanced
het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
in UTR wt het-del het-del balanced balanced
het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del balanced balanced
het-del het-del balanced balanced
in UTR wt het-del het-del balanced balanced
het-del het-del balanced balanced
in UTR ND het-del het-del balanced balanced
-146 ATG (C250T) het-del het-del balanced balanced
-124 ATG (C228T) het-del het-del gain balanced
-124 ATG (C228T) het-del het-del balanced balanced
egfr _Kreuztabelle_aktu idh1-r132h atrx
unmethylated mutie
unsure normal mutie
methylated normal norm
unsure normal norm
unmethylated normal norm
unmethylated normal norm
unsure normal norm
unmethylated normal mutie
unsure normal norm
unmethylated normal mutie
unsure mutiert mutie
methylated mutiert norm
unsure mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
unsure mutiert norm
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
unsure mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
unsure mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert norm
unsure mutiert mutie
unsure mutiert mutie
methylated mutiert norm
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
unmethylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert norm
methylated mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
methylated mutiert mutie
methylated mutiert mutie
unsure mutiert mutie
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TTF
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Integrated 0.122 0.364
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WHO2007 0.127 0.08
Integrated 0.103 0.273
tumor 1180 
tumor 1024 
figure 1 Reuss et al.  
A O OA GBMs GBM GBMo gcGBM GS 
61 63 152 93 12 7 3 14 
A-IDHwt O GBM-IDHmut GBM gcGBM GS 
100 119 14 3 14 
A-IDHmut 
139 16 
initial diagnosis 
integrated diagnosis 
figure 2 Reuss et al.  
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Table 1 
 
Distribution alterations on 1p/7p/10q/19q, IDH1/IDH2 and ATRX in 405 cases 
 
“integrated” diagnosis astrocytoma oligodendroglioma glioblastoma gliosarcoma 
Grade WHO II WHO III WHO II WHO III WHO IV WHO IV 
number 42 113 28 72 136 14 
       
Combined complete 1p/19 loss 
 
0/42 0/113 28/28 72/72 0/136 0/14 
1p loss or 19q loss or combination with 
either or both losses being partial 
11/42 21/113 0/28 0/72 29/136 2/14 
       
Combined complete 7p gain /10q loss 
 
1/42 0/113 0/28 1/72 81/136 13/14 
7p gain or 10q loss including partial 
alterations 
 
9/42 33/113 2/28 7/72 123/136 13/14 
No 7p gain and no 10q loss 
 
32/42 80/113 26/28 64/72 11/136 1/14 
EGFR amp 0/42 0/113 0/28 0/72 38/136 1/14 
       
ATRX loss 
 
38/42 101/113 0/28 2/72 25/136 1/14 
and IDH1/2 mutation 37/38 99/101  2/2 13/25 0/1 
and H3F3A mutation  1/101   8/25 0/1 
       
IDH1-R132H positive 
 
33/42 79/113 22/28 60/72 12/136 0/14 
IDH1 mutation 
 
38/42 102/113 22/28 67/72 13/45 0/1 
IDH2 mutation 
 
0/42 1/113 6/28 5/72 1/50 0/1 
       
TERT promoter mutation 
 
1/21 2/85 16/18 52/61 62/90 13/14 
MGMT promoter methylation* 24/27 71/83 22/22 70/70 56/119 3/13 
*: only cases with a clear-cut MGMT promoter status (methylated or unmethylated) are listed 
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Table 2 
Comparison of WHO 2007 and “integrated” diagnostic approaches with clinical outcome in 100 NOA-
04 patients 
 WHO 2007 “integrated” diagnosis 
Diagnosis A OA O A-IDHmut O A-IDHwt GBM-IDHwt 
number 47 37 16 41 37 8 14 
        
1p/19-codel 3 23 11 0 (def) 37 (def) 0 (def) 0 (def) 
IDH-mut 30 34 14 41 (def) 37 0 (def) 0 
7p-gain 13 4 2 4 2 2 11 
10q-loss 19 4 2 7 2 2 14 
7p-gain/10q-loss 10 1 0 0 0 0 (def) 11 (def) 
EGFR-amp 7 1 0 0 0 0 (def) 8 (def) 
        
        
ATRX loss 27 12 3 36 2 4 0 
        
        
Mean OS 1536 2182 n/r 2182 n/r 1883 706 
Mean TTF 1175 1840 1684 1691 n/r 1325 374 
        
 
(def) this parameter is employed for definition of the “integrated” diagnosis. n/r ~ not reached 
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Figure legends 
 
Figure 1 
Two typical copy number profiles: Tumor 1180 exhibits 1p/19q codel. Note that the entire 
chromosomal arms are missing. In addition, this tumor also exhibits gain on chromosome 16. Tumor 
1024 exhibits partial losses on both, 1p and 19q. These losses do not qualify for the 
oligodendroglioma defining 1p/19q codel. In addition, this tumor also exhibits gains on 7p, 7q and 19p 
and EGFR amplification (arrow) as well as losses on 9p, 10p, 10q and 17q. 
 
Figure 2 
Changes from initial to integrated diagnosis in 405 adult patients with supratentorial glioma. Width of 
bars indicates relative proportions of the initial tumor groups. A ~ astrocytoma; OA ~ oligoastrocytoma; 
O ~ Oligodendroglioma; GBM ~ glioblastoma; GBMo ~ glioblastoma with oligodendroglial component; 
GBMs ~ secondary glioblastoma; gcGBM ~ giant cell glioblastoma; GS ~ gliosarcoma 
 
Figure 3 
Examples of ATRX staining. a-d: Diffuse (a, 1313; b, 1043) and anaplastic astrocytomas (c, 1368; d, 
1383) with loss of ATRX staining in tumor cell nuclei. The number of non-neoplastic cells, which serve 
as internal controls, varies markedly between samples but endothelial cells are always positive. e, f: 
Oligodendroglioma (e, 1073) and anaplastic oligodendroglioma (f, 1308) with strong nuclear ATRX 
staining. g: glioblastoma (1188) with strong nuclear ATRX expression. Necrotic cells may stain 
negative. h: glioblastoma (1187) with thermally damaged tissue in which ATRX staining is artificially 
lost. 
 
Figure 4 
Overview of molecular alterations in 405 patients with “integrated” diagnosis. Each column represents 
a patient. Red boxes ~ tested positive; dark grey ~tested balanced for chromosomal status or negative 
for mutations; light grey ~ IDH1-R132H mutation tested negative, not tested for rare mutations; white ~ 
not tested.*: 1p/19q status set per definition. 
 
Figure 5 
Changes from initial to integrated diagnosis in 100 patients with anaplastic astrocytomas, 
oligoastrocytomas and oligodendrogliomas diagnosed according to WHO 2007 from the NOA04 study. 
Width of bars indicates relative proportions of the initial tumor groups. A ~ astrocytoma; OA ~ 
oligoastrocytoma; O ~ Oligodendroglioma; GBM ~ glioblastoma 
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Figure 6 
OS (panels on left) and TTF (panels on right) of 100 NOA-04 patients with anaplastic astrocytomas, 
oligoastrocytomas and oligodendrogliomas diagnosed according to WHO 2007 (upper panels) and 
receiving an “integrated” diagnosis (middle panels). Lower panels show prediction error curves for OS 
(left) and TTF (right), depicting the Brier score over time. A higher prediction error indicates a greater 
difference between observed (known) survival status of patients and the survival probabilities 
calculated from the respective Cox model, i.e. less prediction accuracy. 
OS ~ overall survival; TTF ~ time to treatment failure 
 
Figure 7 
Diagram for efficient use of IDH1/ATRX-IHC, 1p/19q analysis and IDH sequencing for diagnosing adult 
diffuse astrocytic and oligodendroglial tumors 
- ~ no expression; +~ expression; wt – wild type status; codel – codeletion i.e. combined loss of the 
entire chromosomal arms; noncd ~ no codeletion 
* -  the series is biased towards diffuse astrocytomas and oligodendrogliomas 
** - two tumors had both, ATRX loss and 1p/19q codel, and received the integrated diagnosis 
oligodendroglioma 
*** - the small group of IDHwt astrocytomas is likely to contain further underdiagnosed GBM 
